Isomorphic Labs

Isomorphic Labs is a British artificial intelligence drug-discovery company founded in November 2021 as a subsidiary of Alphabet Inc., spun out of Google DeepMind following DeepMind's foundational AlphaFold 2 protein-structure prediction breakthrough. The company is headquartered in London and is led by Demis Hassabis, the Google DeepMind CEO and 2024 Nobel Laureate (Chemistry, for AlphaFold). Isomorphic Labs applies AlphaFold-derived AI methods to drug-discovery research, with explicit positioning at the intersection of foundational AI research and pharmaceutical drug design. The company has pharmaceutical industry partnerships including Eli Lilly and Novartis, with reported $100 million-plus committed across these partnerships.

At a glance

• Founded: November 2021 as an Alphabet subsidiary.
• Status: Subsidiary of Alphabet Inc. Distinct from Google DeepMind but with research-collaboration relationship.
• Funding: Alphabet internal capital. April 2024 external funding round of $600 million led by Thrive Capital with Alphabet, GV (Google Ventures) participation.
• CEO: Demis Hassabis, Founder and Chief Executive Officer. Concurrent CEO of Google DeepMind. 2024 Nobel Laureate (Chemistry).
• Other notable leadership: Senior research-and-business leadership including former pharmaceutical-industry executives. Specific senior leadership profiles have evolved through 2024 to 2026.
• Open weights: Limited. Isomorphic Labs operates as a commercial drug-discovery organization with proprietary research; AlphaFold (the foundational model from Google DeepMind) is open-source.
• Flagship outputs: AI drug-discovery research; specific pre-clinical and clinical pipeline details have been limited.

Origins

Isomorphic Labs was founded in November 2021 by Demis Hassabis as an Alphabet subsidiary, spun out of Google DeepMind to commercialize the AlphaFold protein-structure prediction research. The November 2020 AlphaFold 2 breakthrough had achieved superior protein-structure prediction capability that was characterized in Nature as a fundamental breakthrough in structural biology. Isomorphic Labs was structured to apply AlphaFold-derived AI methods to drug-discovery research.

The 2022 to 2024 period saw pharmaceutical industry partnerships. Eli Lilly partnership (January 2024) and Novartis partnership (January 2024) provided commercial validation of the AI-and-drug-discovery thesis, with reported total commitments exceeding $100 million across the partnerships and pipeline-progression milestones.

The April 2024 external funding round of $600 million led by Thrive Capital, with continued Alphabet and GV participation, was the company's first external capital raise. The round provided capital base for continued research and pharmaceutical partnership expansion.

The 2024 to 2026 period has seen continued AI drug-discovery research, including advances through AlphaFold 3 (jointly developed with Google DeepMind) and the broader Isomorphic Labs proprietary platform. Demis Hassabis received the 2024 Nobel Prize in Chemistry alongside John Jumper for the AlphaFold research, providing additional credibility.

Mission and strategy

Isomorphic Labs' stated mission is to use AI to accelerate drug discovery and to enable faster development of new therapeutics. The strategy combines foundational AI research (in collaboration with Google DeepMind) with pharmaceutical-partner relationships and proprietary drug-discovery pipeline development.

Models and products

• AlphaFold-derived AI methods. Foundational protein-structure prediction and other computational biology methods.
• AI drug-discovery platform. Proprietary internal platform combining AI methods with pharmaceutical-research workflows.
• Pipeline candidates. AI-discovered drug candidates progressing through pre-clinical research with pharmaceutical partners.

Leadership

• Demis Hassabis, Founder and CEO. Concurrent Google DeepMind CEO; 2024 Nobel Laureate.
• Senior research-and-business leadership team including former pharmaceutical-industry executives.

Funding and backers

• Alphabet internal capital (founding period through 2024).
• April 2024 external round: $600 million led by Thrive Capital with Alphabet and GV participation.
• Pharmaceutical partnerships: Eli Lilly (January 2024), Novartis (January 2024), with reported total commitments exceeding $100 million.

Industry position

Isomorphic Labs occupies a structurally distinctive position as the principal AI-and-drug-discovery company globally, with the AlphaFold research lineage, the Hassabis Nobel-Laureate leadership, the Alphabet parent-company structural support, and the pharmaceutical partnerships differentiating the company.

Competitive landscape

• Recursion Pharmaceuticals, BenevolentAI, Insilico Medicine. AI-and-drug-discovery peers.
• Inceptive. AI biology peer with RNA-therapeutic focus.
• Periodic Labs. AI-and-physical-science Insurgent.
• Pharmaceutical incumbents. Eli Lilly, Novartis, Pfizer, and other organizations have their own AI drug-discovery research efforts.

Outlook

• Pipeline progression toward clinical trials.
• Continued pharmaceutical-partnership expansion.
• AlphaFold and other foundation-model research advances.
• Potential additional commercial expansion or eventual standalone listing.

Sources

• Isomorphic Labs official site. Company reference.
• Wikipedia: Isomorphic Labs. Comprehensive company history reference.
• Wikipedia: Demis Hassabis. Founder biographical reference.